4.6 Review

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review

Journal

CANCERS
Volume 13, Issue 9, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13092067

Keywords

ovarian cancer; mass spectrometry; proteomics; genomics; cancer tissue; biomarker

Categories

Funding

  1. PE I + D + i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) [PT17/0019]
  2. ERDF
  3. Spanish Ministry of Science and Innovation [CTQ2016-80364-P]
  4. Centro de Excelencia Severo Ochoa 2013-2017 [SEV-2012-0208]
  5. Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya [2017SGR595, 2017SGR1661]
  6. Instituto de Salud Carlos III [PI15/02238, PI18/01017, CPII18/00027]
  7. Ministerio de Economia y Competitividad y Fondos FEDER [RTC-2015-3821]
  8. Spanish Ministry of Science and Innovation
  9. Centro de Excelencia Severo Ochoa
  10. CERCA Programme/Generalitat de Catalunya
  11. Vall d'Hebron Research Institute (VHIR)
  12. Centre for Genomic Regulation (CRG)

Ask authors/readers for more resources

This manuscript reviews the management strategies and molecular advances in high-grade serous ovarian cancer, emphasizing the role of proteomics in studying tumor biology and guiding the development of new biomarkers and therapeutic targets. High-grade serous ovarian cancer remains a challenging subtype characterized by late diagnosis and frequent relapse despite standardized treatment. The integration of proteomics with genomics holds promise for improving our understanding of the disease and developing more effective treatments.
Simple Summary In this manuscript, we review the management strategies available for high-grade serous ovarian cancer patients and the molecular advances that are helping improve our understanding of the tumor and its response to treatment. We emphasize the role that proteomics is now playing in the study of ovarian cancer tumors and how its integration with genomics can guide the development of new biomarkers and therapeutic targets. High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available